Proactive Investors - Run By Investors For Investors

AusCann Group pilot study reveals unique capsule for cannabinoid medicines

The study has developed a new hard capsule to deliver its cannabinoid medicines.
cannabis leaf near green pills and stethoscope
The new hard capsule form will be a game changer for doctors and patients

AusCann Group Holdings Ltd (ASX:AC8) has completed a successful pilot study of its final dose form for its proprietary cannabinoid medicines.

Through its research, AusCann has developed a unique effective stable oral dose form which provides consistent and stable dosages of the active cannabinoids.

The study was carried out over the past ten months to be ready for the release of AusCann’s first cannabinoid medicines in first half of 2019.

READ: Auscann Group raises more capital, well-funded for manufacturing cannabinoid medicines in Australia

AusCann’s managing director Elaine Darby said: “AusCann has developed something truly unique in the world of cannabinoid medicines.

“Delivery of consistent and stable products has been an issue that plagues the cannabis medicine industry.

“This new hard capsule will be a game changer for doctors and patients as it is easy to use and will give consistent treatment outcomes every time.

“We are thrilled with the success of this study and look forward to releasing these new pharmaceuticals next year.”

Well-funded to deliver on strategy

Following a placement and subsequent share purchase plan last month, AusCann is well-funded to deliver on its path of developing safe, efficacious, clinically-validated and cost-effective cannabinoid medicines.

Patent lodged for unique capsule dose

Currently, medicinal cannabis is typically administered via oral liquids, liquid sprays, hard or soft-shell gelatin capsules containing cannabinoids dissolved in oils, or inhalation of dried material or extracts.

The main drawback to these formulations is the stability of the active cannabinoids which results in variability in the composition and the efficacy of the formulations.

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full AC8 profile View Profile

AusCann Group Holdings Ltd Timeline

Related Articles

muffins and cannabis
November 30 2018
Dehydratech is essentially a delivery system that allows drugs and vitamins to get into the bloodstream quicker, while making them taste and smell better at the same time
November 03 2018
Back Home Medical Cannabis Corp has agreed on a 24,000-kilogram three-year production and supply agreement
Cannabis leaf
November 19 2018
With the legalisation of recreational cannabis in Canada in October, and the US expected to follow suit, the company has its sights set on building up the very best in the industry

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use